2013-02-26 07:16:29 -

Nestlé S.A. /
New US acquisition for Nestlé Health Science will strengthen Brain Health and 
Metabolic Health portfolios with new medical foods 
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

Nestlé Health Science, a fully owned subsidiary of Nestlé, has agreed to acquire
the business of Pamlab, a US-based company with an innovative portfolio of
medical food products for use under medical supervision in the nutritional
management of patients with mild cognitive impairment, depression and diabetic
peripheral neuropathy.

Strategic fit
The acquisition further strengthens Nestlé Health Science's capacity to deliver
personalised healthcare to address chronic medical conditions through nutrition,
especially in the areas of metabolic health and brain health.

"The acquisition of the Pamlab business is aligned with our strategic   ambition
to provide science-based nutritional solutions for people with chronic medical
conditions. Pamlab will particularly strengthen our brain health platform and
provide us an additional foothold in metabolic health in the US," said Luis
Cantarell, Nestlé Health Science President and Chief Executive Officer.

"By leveraging our nutrition heritage and US operations with Pamlab's proven
expertise in medical foods and strong sales force capabilities, together we can
play a key role in helping to manage certain chronic diseases and improve the
quality of patients' lives," he added.

Commercialised products that improve quality of life
Pamlab's portfolio of prescription medical food products for use under medical
supervision includes Metanx, one of their key products that is formulated to
meet the distinct nutritional requirements of patients with diabetes to help
restore the metabolic processes associated with peripheral neuropathy.

This serious condition is common among those with Type 2 Diabetes, where the
patient's peripheral blood flow has been compromised and their nerves damaged.

Pamlab also makes Deplin, a medical food specifically formulated to provide
necessary nutritional support for certain people on prescribed antidepressant
therapy for clinical depression.

Deplin contains l-methylfolate, the active ingredient of folate, to help balance
three neurotransmitters associated with mood: serotonin, dopamine and
norepinephrine.

In addition, the company produces CerefolinNAC, a medical food to help address
distinct metabolic nutritional needs associated with mild cognitive impairment.

A common purpose
"We are excited to join forces with Nestlé Health Science, and we share their
commitment to personalised nutrition," said Eric Wingerter, Pamlab President and
Chief Executive Officer.

"With their support, we will accelerate the development and deployment of our
innovative nutritional solutions for people with chronic metabolic and
neurologic conditions.
"We are united by a common purpose, and a common culture, founded on our passion
for patients to make a difference in people's lives."

Building on ambition towards science-based nutritional solutions
Nestlé Health Science's core business provides nutritional solutions for people
with specific dietary needs related to illness or disease states in the area of
ageing medical care, critical care and surgery, and paediatric medical care.

The company is also developing new approaches to chronic diseases in the areas
of gastrointestinal (GI) health, metabolic health and brain health.

In 2012 Nestlé Health Science agreed to form a 50/50 joint venture named
Nutrition Science Partners, Ltd to develop nutritional and medicinal products
derived from botanical plants to address gastrointestinal disorders. This
transaction is subject to regulatory approval.

Other acquisitions and partnerships include: Prometheus Laboratories, a U.S.
firm specialising in diagnostics and licensed speciality pharmaceuticals in GI
and oncology; Vitaflo, a provider of clinical nutritional solutions for infants,
children and adults with genetic disorders that affect how food is processed by
the body; and a minority investment in U.S firm Accera, specialising in medical
foods intended for the clinical dietary management of mild to moderate
Alzheimer's disease.

Terms of acquisition
The terms of Nestlé Health Science's acquisition of Pamlab are not being
disclosed. The transaction is subject to regulatory approval.


Media enquiries
Tel: +41 21 924 2200
Email: mediarelations@nestle.com



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Nestlé S.A. via Thomson Reuters ONE
[HUG#1680988]